MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Codexis Inc

Fermé

SecteurSoins de santé

2.65 0.38

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.55

Max

2.68

Chiffres clés

By Trading Economics

Revenu

7.4M

-13M

Ventes

7.8M

15M

BPA

-0.16

Marge bénéficiaire

-86.587

Employés

188

EBITDA

7.6M

-13M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+139.77% upside

Dividendes

By Dow Jones

Prochains Résultats

30 oct. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-6.3M

226M

Ouverture précédente

2.27

Clôture précédente

2.65

Sentiment de l'Actualité

By Acuity

44%

56%

144 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

Codexis Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 oct. 2025, 18:13 UTC

Principaux Mouvements du Marché

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

17 oct. 2025, 17:05 UTC

Principaux Mouvements du Marché

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

17 oct. 2025, 15:03 UTC

Principaux Mouvements du Marché

Obook Shares Sink Following Public Debut

17 oct. 2025, 14:41 UTC

Principaux Mouvements du Marché

Disc Medicine Shares Surge After FDA Grants Priority Voucher for EPP Drug

17 oct. 2025, 23:25 UTC

Acquisitions, Fusions, Rachats

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 oct. 2025, 22:15 UTC

Market Talk

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 oct. 2025, 21:15 UTC

Market Talk

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

17 oct. 2025, 21:07 UTC

Market Talk

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

17 oct. 2025, 21:07 UTC

Market Talk

Global Equities Roundup: Market Talk

17 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 oct. 2025, 20:34 UTC

Market Talk

Deere Is Reaching the End of Its Downcycle -- Market Talk

17 oct. 2025, 20:27 UTC

Market Talk

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

17 oct. 2025, 19:46 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

17 oct. 2025, 19:45 UTC

Market Talk

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

17 oct. 2025, 18:45 UTC

Market Talk

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

17 oct. 2025, 17:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 oct. 2025, 17:51 UTC

Market Talk

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

17 oct. 2025, 17:44 UTC

Market Talk

EQT Seen With Long-Term Growth Opportunities -- Market Talk

17 oct. 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

17 oct. 2025, 16:20 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

17 oct. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 oct. 2025, 16:14 UTC

Market Talk

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

17 oct. 2025, 16:04 UTC

Market Talk

Home Improvement Demand Is Starting to Pick Up -- Market Talk

17 oct. 2025, 15:58 UTC

Market Talk

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

17 oct. 2025, 15:56 UTC

Résultats

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17 oct. 2025, 15:43 UTC

Market Talk

Global Equities Roundup: Market Talk

17 oct. 2025, 15:43 UTC

Market Talk

Amazon's Earnings Are About Sentiment of Consumers, Not Investors -- Market Talk

17 oct. 2025, 14:58 UTC

Market Talk

Small-Business Trepidation in Canada Points to Economic Decline -- Market Talk

17 oct. 2025, 14:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 oct. 2025, 14:35 UTC

Market Talk
Résultats

American Express's Delayed Card Fee Hike Worries Some Investors -- Market Talk

Comparaison

Variation de prix

Codexis Inc prévision

Objectif de Prix

By TipRanks

139.77% hausse

Prévisions sur 12 Mois

Moyen 6.33 USD  139.77%

Haut 11 USD

Bas 3 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

5 ratings

3

Achat

2

Maintien

0

Vente

Score Technique

By Trading Central

2.25 / 2.53Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

144 / 371Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Codexis Inc

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, the company is currently developing its proprietary ECO Synthesis(tm) manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
help-icon Live chat